Effect of bosentan on exercise capacity in patients with pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension  by Hirashiki, Akihiro et al.
are counteracted by ETRAs targeting ETB but not ETA receptors. ETB
receptors may also regulate ET-1 levels through changes in ECE-1
expression. We postulate that higher concentrations of treprostinil
may be required to reach clinical efﬁcacy in PAH when combined
with non-speciﬁc ETRAs.
doi:10.1016/j.lfs.2013.12.151
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Background: Transthoracic Doppler echocardiography (DE) is useful
for the screening of pulmonary hypertension (PH), which is often
treated by endothelin antagonist, although recent studies have
suggested that estimation of pulmonary artery pressure (PAP) by DE
is frequently inaccurate. This study aimed to examine that functional
tricuspid regurgitation (TR) with geometric alterations caused by right
ventricular dilatation is involved in the diagnostic error of echocardi-
ography for the assessment of PAP. Methods: We conducted a
retrospective cohort study of consecutive 127 patients (male, n = 58,
mean age of 55 years) who received both echocardiography and right
heart catheterization (RHC) during the 2-year period from November
2008 to October 2010. We deﬁned PH as mean PAP N 25 mmHg at rest
by RHC and “accurate estimated echocardiographic value” when it
remained within 10 mmHg of the invasive measurement. Results: A
total of 75 patients (59%)were diagnosed to have PH by RHC.When the
patients were divided into 3 groups; accurate (n= 52), over-estimate
(n= 63) and under-estimate (n= 12), the diagnosis of PH by RHCwas
42% in accurate, 68% in over-estimate, and 83% in under-estimate
groups (P = 0.004). In echocardiography, right ventricular dimension
was signiﬁcantly larger in over-estimate group (accurate, 30.0 ±
5.7 mm; over, 35.3 ± 8.6 mm; under, 32.8 ± 5.2 mm, P = 0.002), and
the severity of TR was signiﬁcantly worse in over-estimate group
(P b 0.0001). Right atrium tended to be larger in both over-estimate and
under-estimate groups than accurate group (accurate, 38.8 ± 5.7 mm;
over, 42.6 ± 8.49 mm; under, 42.7 ± 6.2 mm, P = 0.073). Conclusions:
Our results indicate that the accuracy of DE is not enough for PAP
evaluation, particularly in patients with PH associated with increased
TR grading and enlarged right heart dimension.
doi:10.1016/j.lfs.2013.12.152
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Since the discovery of ET-1, over-expression of ET-1 has been
demonstrated in patients with pulmonary arterial hypertension
(PAH). In contrast to chronic thromboembolic pulmonary hyperten-
sion (CTEPH), patients with PAH have pulmonary vasculopathy (PV).
PV leads to impaired dilatation of affected pulmonary vessels,
impeding the increase of cardiac output (CO) and stroke volume
(SV) during exercise. Peak O2 uptake shows CO, and peak O2-pulse
shows SV during cardiopulmonary exercise testing (CPX). To
investigate the increase of CO during exercise, we performed CPX
in 12 patients with PAH and 7 patients with CTEPH. Predicted peak
O2 uptake (45.5 ± 8.0 vs. 60.6 ± 13.4%, p b 0.01) and predicted peak
O2-pulse (55.6 ± 7.6 vs. 69.1 ± 6.9%, p b 0.01) were signiﬁcant
higher in CTEPH than PAH. Diffusion capacity for carbon monoxide
(%DLco: 40.3 ± 13.7 vs. 62.2 ± 13.9%, p b 0.01) was also signiﬁcantly
higher in CTEPH than PAH, however there was no correlation
between %DLco and peak O2 uptake or peak O2-pulse. While, there
was no difference in mean pulmonary arterial pressure (mPAP: 31 ±
6.8 vs. 30.1 ± 7.0 mmHg, n.s.), cardiac output (CO: 4.1 ± 0.6 vs. 4.4 ±
0.4 L/min, n.s.), and pulmonary vascular resistance (PVR: 5.2 ± 2.0 vs.
5.2 ± 2.8 wood units, n.s.) at rest. Our data indicate that, regardless of
hemodynamic, both lower peak O2 uptake and peak O2-pulse show PV
impeding the increase of CO during exercise. CPX can predict the onset
of PAH by detection of PV in early stage.
doi:10.1016/j.lfs.2013.12.153
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Introduction: Increased endothelin-1 (ET-1) is a hallmark of
pulmonary arterial hypertension (PAH), and contributes to its patho-
genesis. The factors controlling ET-1 in PAH are poorly understood.
Vascular endothelial growth factor (VEGF) blockade results in PAH-like
lesions in animal models, and has caused PAH in humans. The effects of
VEGF on ET-1 production by human lung blood microvascular
endothelial cells (HMVEC-LBl) are unknown. Methods: We exposed
HMVEC-LBl (Lonza Inc.) in-vitro to human VEGF121 (40 ng/ml) in
serum-free medium for 7 h, in the absence or presence of the VEGF
receptor antagonist, SU5416 (Cayman Chemical, 3 and 10 μM). ET-1
production was measured in the supernatant. Phosphorylation of VEGF
receptor 2 (VEGFR2) was measured by western blotting after exposure
to VEGF ± SU5416 for 5 and 10 min. Results: VEGF effectively caused
VEGFR2 phosphorylation, which was blocked by SU5416. VEGF
decreased ET-1 production by 29%. In the absence of VEGF, SU5146
increased ET-1 production, by 16% at 10 μM, and SU5146 was able to
completely abolish the VEGF effect on ET-1 production. Conclusion:
VEGF may promote vascular health by decreasing ET-1 production in
HVMEC-LBl. Blockade of VEGF signalling by SU5416 increases ET-1
levels and may thereby contribute to the pathogenesis of pulmonary
hypertension seen with VEGF blockade.
doi:10.1016/j.lfs.2013.12.154
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Background: Endothelin receptor antagonists (ERA) improve the
prognosis of patients with pulmonary arterial hypertension (PAH).
However, only limited data are available on the effect of treatment
with the ERA bosentan on exercise capacity assessed with cardio-
pulmonary exercise testing (CPX) in patients with PAH or inoperable
chronic thromboembolic pulmonary hypertension (CTEPH). Purpose:
To investigate the effect of the oral, dual-ERA bosentan on exercise
capacity in patients with PAH or inoperable CTEPH by means of CPX.
Methods: Fifteen consecutive PAH (mean age, 47 ± 21 years) and 9
consecutive inoperable CTEPH patients (mean age, 49 ± 12 years)
with World Health Organization Functional Class II to IV were
treated with bosentan. All patients underwent cardiac catheteriza-
tion, echocardiography, and CPX at baseline. CPX was performed
both prior to initiation of bosentan therapy and after 6 months.
Results: In PAH patients, peak VO2 signiﬁcantly increased from
13.8 ± 6.8 mL/kg/min at baseline to 16.8 ± 7.2 mL/kg/min after
6 months (P b 0.01). Similarly, VE/VCO2 slope also signiﬁcantly
decreased from 56.8 ± 22.5 to 48.9 ± 17.5 (P b 0.05). However, in
CTEPH patients, there were no signiﬁcant differences in peak VO2 or
VE/VCO2 slope between the before and after bosentan therapy
values (P = 0.35, P = 0.67, respectively). The medication was well
tolerated by all patients, and there was no evidence of drug-related
liver dysfunction. Conclusions: Bosentan therapy improves exercise
capacity in patients with PAH within a relatively short period.
However, the effect is not seen in patients with CTEPH.
doi:10.1016/j.lfs.2013.12.155
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Background: Bosentan and sildenaﬁl are often administered togeth-
er for the treatment of PAH. Bosentan is a known inducer of CYP3A4 in
chronic use and therefore, the plasma concentration of sildenaﬁl is
decreased almost by half when co-administered. In the course of daily
life, patients tend to take these medicines at the same time in the
morning and the evening. We investigated how the plasma concentra-
tion of sildenaﬁl changed when bosentan/sildenaﬁl was taken before-
hand with the other. Methods: A randomized, open-label crossover
study was conducted in PAH patients of WHO functional class III,
who chronically received both bosentan and sildenaﬁl. Patients were
randomly assigned to either Pattern 1 or 2, both of which consisted of
three phases as follows; phase S: patients take sildenaﬁl 3 h prior to
bosentan, phase B: patients take bosentan 3 h prior to sildenaﬁl, and
phase C: patients take sildenaﬁl and bosentan simultaneously (control).
We collected blood samples on the last day of each phase andmeasured
the plasma concentration of sildenaﬁl using liquid chromatography-
tandem mass spectrometry. Results: Six patients entered the study. In
sildenaﬁl Cmax, phase S was 72.9 ± 40.9 (ng/ml, mean± S.D) and it
was signiﬁcantly lower than phase C (P= 0.0215). Phase B was 99.6 ±
33.9 with no signiﬁcant difference with phase C (P= 0.6173). In
sildenaﬁl AUC0-8, phase S was 108.2 ± 126.4 (h/ng/ml, mean± S.D)
and phase B was 240.7 ± 121.8. Neither phase proved signiﬁcant
difference with that of phase C (203.5 ± 81.3, P = 0.3213 and 0.1999,
respectively). Conclusion: It is indicated that there is a short-term drug
interaction between bosentan and sildenaﬁl which may be relevant to
CYP3A4 metabolism.
doi:10.1016/j.lfs.2013.12.156
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Rationale: A novel dual ETA/ETB receptor antagonist, macitentan,
has been reported to signiﬁcantly reduce morbidity and mortality in
patients with pulmonary arterial hypertension (PAH) (SERAPHIN
study). However, the underlying mechanisms warrant further
preclinical investigations. We have established a rat model of PAH,
which develops severe pulmonary hypertension (PH) with occlusive
pulmonary arteriopathy indistinguishable from that in PAH patients.
This study investigated the effects of macitentan on hemodynamics
and histopathology in the rat model with established severe PAH.
Method and results: Rats received a single subcutaneous injection of
20 mg/kg SU5416, a VEGF blocker, and then exposed to 3-week
hypoxia (10% O2) followed by 5 weeks of normoxia. Eight weeks
after the SU5416 injection, in comparison with normal rats, all rats
developed severe PH (RV systolic pressure: 23 ± 6 vs. 102 ± 15mmHg,
n = 4 or 5 for each, p b 0.001) with RV hypertrophy (the mass ratio of
RV to LV pulse septum: 0.23 ± 0.01 vs. 0.77 ± 0.05, p b 0.001). Five-
week treatmentwithmacitentan (30 mg/kg/day, orally, fromweek 3 to
8) signiﬁcantly reduced RV systolic pressure (41 ± 5 mmHg, n = 6,
P b 0.05) and hypertrophy (0.36 ± 0.03, n = 7, P b 0.005) without
decreasing cardiac output. Also, macitentan signiﬁcantly attenuated
the medial wall thickness and complex occlusive lesions in PAH
rats by histological examination. Conclusion: Chronic treatment with
macitentan markedly hemodynamically and histopathologically im-
proved PAH in SU5416/hypoxia/normoxia-exposed rats. The improve-
ment of arteriopathy may in part contribute to the beneﬁcial effects of
macitentan on PH.
doi:10.1016/j.lfs.2013.12.157
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